Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Cochrane Canada to lose primary funding

Roger Collier
CMAJ July 14, 2015 187 (10) E304; DOI: https://doi.org/10.1503/cmaj.109-5091
Roger Collier
CMAJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

The Canadian Institutes of Health Research (CIHR) will not renew funding for Cochrane Canada after its existing commitment expires in September 2015. CIHR has been the primary funder, providing about $17 million since 2005 to Cochrane Canada, which produces systematic reviews of research to promote evidence-based decision-making in health care.

“What Cochrane does is valuable to the dentist on Main Street, to the physiotherapist on Main Street, to the nurse in a station up North,” said Dr. Jeremy Grimshaw, director of Cochrane Canada. “Cochrane is the interface between primary studies and health decision-making. It helps a wide range of stakeholders make evidence-informed decisions.”

CIHR has funded Cochrane using a direct-grant approach, a process that is peer reviewed but noncompetitive. It is used to fund work of strategic importance that can be done by only one group. According to CIHR, there are now other parties doing similar work to Cochrane Canada.

“New actors in the field of moving research evidence into practice through the creation and updating of high-quality systematic reviews now exist and CIHR believes that they deserve the same opportunity to apply through a fair process,” stated a CIHR media representative in an email. “The Canadian Cochrane Centre is encouraged to apply for continued support through the same methods used by CIHR to award funding to other world-leading scientific research.”

An invitation to compete in the open operating-grant process, however, is somewhat disingenuous, said Grimshaw. That process is intended for investigator-led, hypothesis-driven research. “They are basically asking a square peg to apply for a round hole,” said Grimshaw. “My concern is that it will fail not because of the value of what we do but because it is the wrong funding mechanism for an enabling platform like Cochrane.”

According to Grimshaw, Cochrane Canada, one of 14 Cochrane centres around the world, has been highly productive in the past five years, producing more than 300 new or updated systematic reviews, training nearly 3000 new reviewers and leading almost 100 knowledge translation events. Without the CIHR funding, that productivity will be dramatically reduced, said Grimshaw, and that will lead to a reduction in systematic-review expertise in Canada.

“It will have a reputational impact on Canada. It is remarkable that a country involved at the ground floor in Cochrane and evidence-based medicine is thinking about getting out of it,” said Grimshaw. “At the moment, Canada is, sadly for us, the only geographical area where there are major concerns about Cochrane funding.”

Other benefits of Cochrane Canada include collaboration with reviewers around the world, fulfillment of an international obligation to contribute to evidence-based medicine and the provision of a Canadian context for medical research, according to Dr. Jim Woodgett, director of research for the Lunenfeld–Tanenbaum Research Institute at Mount Sinai Hospital in Toronto. The value of the organization may be compromised, however, if it is forced to seek more funding from other sources.

“That is why the CIHR funding is so important. I don’t think Cochrane Canada will disappear without CIHR funding, but it gave them stability and, more importantly, it gave them independence,” said Woodgett. “There are alternative sources of funding but it will be more tainted.”

The timing of this news also couldn’t be much worse, said Woodgett, following so closely after the death of Dr. David Sackett, the first chair of the Cochrane Collaboration Steering Group. “It was just the wrong time to kick Cochrane Canada in the backside — at the same time as losing the father of this whole area of evidence-based medicine.”

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 187 (10)
CMAJ
Vol. 187, Issue 10
14 Jul 2015
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cochrane Canada to lose primary funding
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cochrane Canada to lose primary funding
Roger Collier
CMAJ Jul 2015, 187 (10) E304; DOI: 10.1503/cmaj.109-5091

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Cochrane Canada to lose primary funding
Roger Collier
CMAJ Jul 2015, 187 (10) E304; DOI: 10.1503/cmaj.109-5091
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Trudeau promises to boost federal health transfers when the pandemic is over
  • Does shaming have a place in public health?
  • Should Canada aim for #CovidZero?
Show more News

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire